cemiplimab
regeneron,sanofi
['cemiplimab']
ana oaknin presenting empower trial long-term survival data #esmo2022: cemiplimab monotherapy improves os in recurrent or metastatic #cervicalcancer regardless of pd-l1 status 
#gynonc fellow based in Innsbruck, Austria @IJGConline early career editorial board @imed_tweets alumni, ???? ?? ???? #ESGO2022Ambassador